anastrozole and Carcinoma, Ductal, Breast studies

Carcinoma, Ductal, Breast: An invasive (infiltrating) CARCINOMA of the mammary ductal system (MAMMARY GLANDS) in the human BREAST.

Research Excerpts

Excerpt	Relevance	Reference
"This analysis has identified a significant continuing reduction in breast cancer with anastrozole in the post-treatment follow-up period, with no evidence of new late side-effects."	9.34	Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial. ( Bonanni, B; Cawthorn, S; Cuzick, J; Dowsett, M; Evans, DG; Forbes, JF; Howell, A; Loibl, S; Mansel, RE; Sestak, I, 2020)
"27 compared 5 years of adjuvant anastrozole or exemestane in postmenopausal patients with hormone receptor positive early breast cancer."	9.27	Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27. ( Chen, BE; Goss, PE; Liedke, PER; O'Shaughnessy, J; Parulekar, WR; Ramjeesingh, R; Shepherd, LE; Strasser-Weippl, K; Sudan, G, 2018)
"Third-generation aromatase inhibitors are more effective than tamoxifen for preventing recurrence in postmenopausal women with hormone-receptor-positive invasive breast cancer."	9.22	Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. ( Bonanni, B; Bundred, N; Coleman, RE; Cuzick, J; Eiermann, W; Ellis, I; Forbes, JF; Holcombe, C; Howell, A; Jones, L; Levy, C; Neven, P; Sestak, I; Stierer, M; von Minckwitz, G, 2016)
"Anastrozole effectively reduces incidence of breast cancer in high-risk postmenopausal women."	9.19	Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. ( Bonanni, B; Cawthorn, S; Cuzick, J; Dowsett, M; Forbes, JF; Howell, A; Knox, J; Mansel, RE; Palva, T; Roche, N; Saunders, C; Sestak, I; von Minckwitz, G, 2014)
"Tamoxifen and anastrozole are widely used as adjuvant treatment for early stage breast cancer, but their hepatotoxicity is not fully defined."	9.19	A prospective, randomized study on hepatotoxicity of anastrozole compared with tamoxifen in women with breast cancer. ( Chen, D; Deng, Y; Feng, G; He, P; Hu, R; Huang, T; Li, E; Li, L; Li, Y; Liang, Z; Lin, Y; Liu, J; Lu, Y; Ma, R; Su, F; Sun, S; Tong, Z; Wang, S; Wang, X; Wu, Y; Xu, Z; Zhang, H; Zhang, X; Zhang, Y; Zhao, Y, 2014)
"A total of 391 postmenopausal Japanese women with estrogen receptor-positive breast cancer and treated with adjuvant anastrozole were enrolled from 28 centers for assessment of patient-reported outcomes (PROs) in this prospective cohort study (SAVS-JP, UMIN000002455)."	7.83	Risk factors for joint symptoms in postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes. ( Baba, M; Egawa, C; Hashimoto, T; Hidaka, T; Hirokaga, K; Ichii, S; Kikawa, Y; Kitatsuji, K; Kokufu, I; Konishi, M; Konishi, Y; Kono, S; Matsumoto, T; Minohata, J; Mitsunobu, M; Miya, A; Miyashita, M; Miyauchi, K; Miyoshi, Y; Nishikawa, H; Nishino, M; Oh, K; Okuno, T; Sakita, I; Sakoda, Y; Suwa, H; Takao, S; Wakita, K; Yamagami, K, 2016)
"For postmenopausal women with HR+ early-stage breast cancer, letrozole is more likely to be cost effective vs."	7.76	Cost effectiveness of letrozole versus anastrozole in postmenopausal women with HR+ early-stage breast cancer. ( Delea, TE; Guo, A; Lipsitz, M, 2010)
"We report a 69-year-old woman with breast cancer who was effectively treated with letrozole as a second-line therapy after becoming resistant to anastrozole."	7.76	[Advanced breast cancer in a patient achieving long-term SD after letrozole administration for liver metastasis developing during anastrozole therapy]. ( Fujimoto, A; Goto, K; Ichinose, Y; Kobayashi, T; Sasaoki, T; Uchida, S, 2010)
"We report three cases with advanced breast cancer were treated with a weekly dose of paclitaxel (TXL)."	7.73	[Three cases of advanced breast cancer successfully treated with a weekly dose of paclitaxel]. ( Katsumine, Y; Noda, N; Osawa, I; Uehara, S; Yuasa, H, 2005)
"This analysis has identified a significant continuing reduction in breast cancer with anastrozole in the post-treatment follow-up period, with no evidence of new late side-effects."	5.34	Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial. ( Bonanni, B; Cawthorn, S; Cuzick, J; Dowsett, M; Evans, DG; Forbes, JF; Howell, A; Loibl, S; Mansel, RE; Sestak, I, 2020)
"We describe a woman with metastatic breast cancer treated with multiple rounds of prior cytotoxic and endocrine therapies, who presented with ipsilateral diaphragmatic paralysis."	5.32	Anastrozole-induced remission of diaphragmatic paralysis from metastatic breast cancer treated with multiple prior therapies. ( Okamura, Y; Sakurai, T; Shimizu, Y; Suzuma, T; Umemura, T; Yang, QF; Yoshimura, G, 2003)
"Anastrozole therapy is a useful treatment for postmenopausal women with ER positive advanced breast cancer."	5.31	[Advanced breast cancer with lung and pleural metastases responsive to anastrozole--a case report]. ( Enomoto, K; Kinoshita, T; Nishimura, M; Okamura, Y; Oura, S; Sakurai, T; Yokochi, H, 2002)
"27 compared 5 years of adjuvant anastrozole or exemestane in postmenopausal patients with hormone receptor positive early breast cancer."	5.27	Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27. ( Chen, BE; Goss, PE; Liedke, PER; O'Shaughnessy, J; Parulekar, WR; Ramjeesingh, R; Shepherd, LE; Strasser-Weippl, K; Sudan, G, 2018)
"Third-generation aromatase inhibitors are more effective than tamoxifen for preventing recurrence in postmenopausal women with hormone-receptor-positive invasive breast cancer."	5.22	Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. ( Bonanni, B; Bundred, N; Coleman, RE; Cuzick, J; Eiermann, W; Ellis, I; Forbes, JF; Holcombe, C; Howell, A; Jones, L; Levy, C; Neven, P; Sestak, I; Stierer, M; von Minckwitz, G, 2016)
"Compared with tamoxifen, anastrozole treatment provided a significant improvement in breast cancer-free interval, mainly in women younger than 60 years of age."	5.22	Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. ( Albain, KS; Brufsky, AM; Cecchini, RS; Cianfrocca, ME; Costantino, JP; Fehrenbacher, L; Ganz, PA; Gross, HM; Hopkins, JO; Julian, TB; Mamounas, EP; Margolese, RG; Seay, TE; Soori, GS; Sturtz, K; Vallow, LA; Whitworth, PW; Wolmark, N; Wozniak, TF, 2016)
"The NSABP B-35 trial compared 5 years of treatment with anastrozole versus tamoxifen for reducing subsequent occurrence of breast cancer in postmenopausal patients with ductal carcinoma in situ."	5.22	Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. ( Albain, KS; Brufsky, AM; Cecchini, RS; Cianfrocca, ME; Costantino, JP; Fehrenbacher, L; Ganz, PA; Gross, HM; Hopkins, JO; Julian, TB; Mamounas, EP; Margolese, RG; Seay, TE; Soori, GS; Sturtz, K; Vallow, LA; Whitworth, PW; Wolmark, N; Wozniak, TF, 2016)
"Eligible newly diagnosed postmenopausal, estrogen receptor positive breast cancer patients awaiting primary surgery received anastrozole daily until surgery."	5.20	Evaluating the feasibility of performing window of opportunity trials in breast cancer. ( Addison, CL; Arnaout, A; Clemons, M; Kuchuk, I; Namazi, M; Pond, GR; Robertson, S; Simos, D, 2015)
"Anastrozole effectively reduces incidence of breast cancer in high-risk postmenopausal women."	5.19	Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. ( Bonanni, B; Cawthorn, S; Cuzick, J; Dowsett, M; Forbes, JF; Howell, A; Knox, J; Mansel, RE; Palva, T; Roche, N; Saunders, C; Sestak, I; von Minckwitz, G, 2014)
"Tamoxifen and anastrozole are widely used as adjuvant treatment for early stage breast cancer, but their hepatotoxicity is not fully defined."	5.19	A prospective, randomized study on hepatotoxicity of anastrozole compared with tamoxifen in women with breast cancer. ( Chen, D; Deng, Y; Feng, G; He, P; Hu, R; Huang, T; Li, E; Li, L; Li, Y; Liang, Z; Lin, Y; Liu, J; Lu, Y; Ma, R; Su, F; Sun, S; Tong, Z; Wang, S; Wang, X; Wu, Y; Xu, Z; Zhang, H; Zhang, X; Zhang, Y; Zhao, Y, 2014)
"A total of 391 postmenopausal Japanese women with estrogen receptor-positive breast cancer and treated with adjuvant anastrozole were enrolled from 28 centers for assessment of patient-reported outcomes (PROs) in this prospective cohort study (SAVS-JP, UMIN000002455)."	3.83	Risk factors for joint symptoms in postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes. ( Baba, M; Egawa, C; Hashimoto, T; Hidaka, T; Hirokaga, K; Ichii, S; Kikawa, Y; Kitatsuji, K; Kokufu, I; Konishi, M; Konishi, Y; Kono, S; Matsumoto, T; Minohata, J; Mitsunobu, M; Miya, A; Miyashita, M; Miyauchi, K; Miyoshi, Y; Nishikawa, H; Nishino, M; Oh, K; Okuno, T; Sakita, I; Sakoda, Y; Suwa, H; Takao, S; Wakita, K; Yamagami, K, 2016)
"Aromatase inhibitors (AIs) are more effective than tamoxifen as neoadjuvant endocrine therapy (NET) for hormone receptor (HR)-positive breast cancer."	3.80	Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer. ( Angelucci, D; Ausili Cefaro, G; Cianchetti, E; Cioffi, P; De Tursi, M; Di Nicola, M; Grassadonia, A; Grossi, S; Iacobelli, S; Iezzi, L; Marinelli, C; Natoli, C; Noccioli, P; Politi, R; Tavoletta, S; Tinari, N; Zilli, M, 2014)
"For postmenopausal women with HR+ early-stage breast cancer, letrozole is more likely to be cost effective vs."	3.76	Cost effectiveness of letrozole versus anastrozole in postmenopausal women with HR+ early-stage breast cancer. ( Delea, TE; Guo, A; Lipsitz, M, 2010)
"We report a 69-year-old woman with breast cancer who was effectively treated with letrozole as a second-line therapy after becoming resistant to anastrozole."	3.76	[Advanced breast cancer in a patient achieving long-term SD after letrozole administration for liver metastasis developing during anastrozole therapy]. ( Fujimoto, A; Goto, K; Ichinose, Y; Kobayashi, T; Sasaoki, T; Uchida, S, 2010)
"We report three cases with advanced breast cancer were treated with a weekly dose of paclitaxel (TXL)."	3.73	[Three cases of advanced breast cancer successfully treated with a weekly dose of paclitaxel]. ( Katsumine, Y; Noda, N; Osawa, I; Uehara, S; Yuasa, H, 2005)
"We report a breast cancer patient who developed acute myeloid leukemia (AML) one year following her adjuvant chemotherapy consisting of cyclophosphamide, adriamycin and 5-fluorouracil."	3.73	t(8;16) AML developed subsequent to breast cancer therapy. ( Akçali, Z; Boğa, S; DemIrhan, B; Karakuş, S; Sahin, FI; Yilmaz, Z, 2006)
"We present a case of breast carcinoma in the axillary ectopic mammary gland and summarize the clinical features of 94 cases, including ours, in Japan."	2.47	A case of ectopic breast cancer with a literature review. ( Kameda, N; Nihon-Yanagi, Y; Okazumi, S; Ueda, T, 2011)
"Although approximately 60 % of breast cancers in premenopausal women are HR positive, the role of neoadjuvant ET in this population is not well defined."	1.42	Management of Premenopausal Women with Neoadjuvant Endocrine Therapy: A Single-Institution Experience. ( Barbie, TU; Ma, C; Margenthaler, JA, 2015)
"The percentage of women≥75 years with breast cancer receiving PET in the south of the Netherlands decreased from 23% in the period 1988-1992 to 12% in 1997-2000, and increased to 29% in 2005-2008."	1.38	Hormone treatment without surgery for patients aged 75 years or older with operable breast cancer. ( Hutschemaekers, S; Nieuwenhuijzen, GA; Roukema, JA; Tjan-Heijnen, VC; van der Sangen, MJ; Voogd, AC; Wink, CJ; Woensdregt, K, 2012)
"We diagnosed her with left breast cancer(luminal A type) T2N0M0, stage IIA."	1.38	[A successful case of a super-elderly breast cancer patient treated with hormone therapy]. ( Aomatsu, N; Asano, Y; Hirakawa, K; Ishikawa, T; Kashiwagi, S; Kawajiri, H; Morisaki, T; Nakamura, M; Onoda, N; Takashima, T, 2012)
"Anastrozole was superior to tamoxifen with respect to TTP (median values of 10."	1.36	[A case of stage IV breast cancer with bone metastases that responded well for long-term to hormonal therapy]. ( Kawachi, H; Kubota, K; Kuwayama, T; Nakagawa, T; Oda, G; Sato, T; Sugihara, K; Yamamoto, K, 2010)
"Fifty-two advanced and female breast cancer patients with measurable and /or bone valuable tumor lesions were observed from June 2003 to September 2006."	1.34	[Clinical study of aromatase inhibitors in advanced breast cancer]. ( Hou, KY; Ji, JF; Jia, TZ; Li, HP; Wang, MP; Wang, YF; Xiao, Y; Zhao, HM, 2007)
"This is the first report of breast carcinoma metastatic to the endometrium in a patient on adjuvant anastrozole therapy."	1.33	Lobular carcinoma of the breast metastatic to the uterus in a patient under adjuvant anastrozole therapy. ( Bolat, F; Erkanli, S; Haberal, A; Kayaselcuk, F; Kuscu, E; Sakalli, H, 2006)
"We describe a woman with metastatic breast cancer treated with multiple rounds of prior cytotoxic and endocrine therapies, who presented with ipsilateral diaphragmatic paralysis."	1.32	Anastrozole-induced remission of diaphragmatic paralysis from metastatic breast cancer treated with multiple prior therapies. ( Okamura, Y; Sakurai, T; Shimizu, Y; Suzuma, T; Umemura, T; Yang, QF; Yoshimura, G, 2003)
"Anastrozole therapy is a useful treatment for postmenopausal women with ER positive advanced breast cancer."	1.31	[Advanced breast cancer with lung and pleural metastases responsive to anastrozole--a case report]. ( Enomoto, K; Kinoshita, T; Nishimura, M; Okamura, Y; Oura, S; Sakurai, T; Yokochi, H, 2002)

Research

Studies (50)

Authors

Clinical Trials (9)

Trial Overview

Trial Outcomes

Clinical Fracture Rate: Number of Participants With Bone Fractures.

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	21 (42.00)	29.6817
2010's	28 (56.00)	24.3611
2020's	1 (2.00)	2.80

Authors	Studies
Cuzick, J	4
Sestak, I	3
Forbes, JF	3
Dowsett, M	3
Cawthorn, S	2
Mansel, RE	2
Loibl, S	1
Bonanni, B	3
Evans, DG	1
Howell, A	3
Correa de Mello, P	1
Brasil, OFM	1
Strasser-Weippl, K	1
Sudan, G	1
Ramjeesingh, R	1
Shepherd, LE	1
O'Shaughnessy, J	1
Parulekar, WR	1
Liedke, PER	1
Chen, BE	1
Goss, PE	1
Munoz, J	1
Kumar, VA	1
Hamilton, J	1
Pasche, LJ	1
Langford, LA	1
Taggart, MW	1
Kamiya-Matsuoka, C	1
Tummala, S	1
Moulder, S	1
Kurzrock, R	1
Cameron, DA	1
Knox, J	1
Saunders, C	1
Roche, N	1
von Minckwitz, G	2
Palva, T	1
Grassadonia, A	1
Di Nicola, M	1
Grossi, S	1
Noccioli, P	1
Tavoletta, S	1
Politi, R	1
Angelucci, D	1
Marinelli, C	1
Zilli, M	1
Ausili Cefaro, G	1
Tinari, N	1
De Tursi, M	1
Iezzi, L	1
Cioffi, P	1
Iacobelli, S	1
Natoli, C	1
Cianchetti, E	1
Lin, Y	1
Liu, J	3
Zhang, X	1
Li, L	1
Hu, R	1
Deng, Y	1
Chen, D	1
Zhao, Y	2
Sun, S	1
Ma, R	1
Zhang, Y	1
Wang, X	2
Li, Y	1
He, P	1
Li, E	1
Xu, Z	1
Wu, Y	1
Tong, Z	1
Huang, T	1
Liang, Z	1
Wang, S	2
Su, F	1
Lu, Y	1
Zhang, H	1
Feng, G	1
Moy, B	1
Specht, MC	1
Lanuti, M	1
Rafferty, EA	1
Lerwill, MF	1
Arnaout, A	1
Robertson, S	1
Kuchuk, I	1
Simos, D	1
Pond, GR	1
Addison, CL	1
Namazi, M	1
Clemons, M	1
Barbie, TU	1
Ma, C	1
Margenthaler, JA	1
Egawa, C	1
Hirokaga, K	1
Takao, S	1
Yamagami, K	1
Miyashita, M	1
Baba, M	1
Ichii, S	1
Konishi, M	1
Kikawa, Y	1
Minohata, J	1
Okuno, T	1
Miyauchi, K	1
Wakita, K	1
Suwa, H	1
Hashimoto, T	1
Nishino, M	1
Matsumoto, T	1
Hidaka, T	1
Konishi, Y	1
Sakoda, Y	1
Miya, A	1
Mitsunobu, M	1
Nishikawa, H	1
Kono, S	1
Kokufu, I	1
Sakita, I	1
Kitatsuji, K	1
Oh, K	1
Miyoshi, Y	1
Bundred, N	1
Levy, C	1
Eiermann, W	1
Neven, P	1
Stierer, M	1
Holcombe, C	1
Coleman, RE	1
Jones, L	1
Ellis, I	1
Margolese, RG	2
Cecchini, RS	2
Julian, TB	2
Ganz, PA	2
Costantino, JP	2
Vallow, LA	2
Albain, KS	2
Whitworth, PW	2
Cianfrocca, ME	2
Brufsky, AM	2
Gross, HM	2
Soori, GS	2
Hopkins, JO	2
Fehrenbacher, L	2
Sturtz, K	2
Wozniak, TF	2
Seay, TE	2
Mamounas, EP	2
Wolmark, N	2
Aomatsu, N	2
Tei, S	1
Haraoka, G	1
Hosoi, K	1
Fujii, N	1
Tsujio, G	1
Hiramatsu, S	1
Wang, E	1
Iwauchi, T	1
Morimoto, J	1
Nishii, T	1
Kosaka, K	1
Uchima, Y	1
Takeuchi, K	1
Marchand, A	1
Georgin-Mège, M	1
Cellier, P	1
Martin, L	1
Avenel-Audran, M	1
Le Corre, Y	1
Sansone, P	1
Ceccarelli, C	1
Berishaj, M	1
Chang, Q	1
Rajasekhar, VK	1
Perna, F	1
Bowman, RL	1
Vidone, M	1
Daly, L	1
Nnoli, J	1
Santini, D	1
Taffurelli, M	1
Shih, NN	1
Feldman, M	1
Mao, JJ	1
Colameco, C	1
Chen, J	1
DeMichele, A	1
Fabbri, N	1
Healey, JH	1
Cricca, M	1
Gasparre, G	1
Lyden, D	1
Bonafé, M	1
Bromberg, J	1
Saha, P	1
Amico, AL	1
Olopade, OI	1
Lerebours, F	1
Rivera, S	1
Mouret-Reynier, MA	1
Alran, S	1
Venat-Bouvet, L	1
Kerbrat, P	1
Salmon, R	1
Becette, V	1
Bourgier, C	1
Cherel, P	1
Boussion, V	1
Balleyguier, C	1
Thibault, F	1
Lavau-Denes, S	1
Nabholz, JM	1
Sigal, B	1
Trassard, M	1
Mathieu, MC	1
Martin, AL	1
Lemonnier, J	1
Mouret-Fourme, E	1
Gottwald, L	1
Gora, E	1
Korczynski, J	1
Piekarski, JH	1
Morawiec, Z	1
Jesionek-Kupnicka, D	1
Sowa, P	1
Cialkowska-Rysz, A	1
Bienkiewicz, A	1
Nihon-Yanagi, Y	1
Ueda, T	1
Kameda, N	1
Okazumi, S	1
Santiago, F	1
Saleiro, S	1
Brites, MM	1
Frutuoso, C	1
Figueiredo, A	1
Hayashi, K	1
Sengoku, N	1
Kosaka, Y	1
Kondou, Y	1
Sugiyama, N	1
Enomoto, T	1
Kuranami, M	1
Watanabe, M	1
Kykalos, S	1
Mantas, D	1
Dimitroulis, D	1
Alexandrou, P	1
Kostakis, A	1
Chen, LR	1
Lipsitz, M	1
Delea, TE	1
Guo, A	1
Ichinose, Y	1
Kobayashi, T	1
Fujimoto, A	1
Uchida, S	1
Sasaoki, T	1
Goto, K	1
Oda, G	1
Nakagawa, T	1
Sato, T	1
Kuwayama, T	1
Yamamoto, K	1
Kawachi, H	1
Kubota, K	1
Sugihara, K	1
Prowell, TM	1
Blackford, AL	1
Byrne, C	1
Khouri, NF	1
Folkerd, E	1
Tarpinian, KS	1
Powers, PP	1
Wright, LA	1
Donehower, MG	1
Jeter, SC	1
Armstrong, DK	1
Emens, LA	1
Fetting, JH	1
Wolff, AC	1
Garrett-Mayer, E	1
Skaar, TC	1
Davidson, NE	1
Stearns, V	1
Wink, CJ	1
Woensdregt, K	1
Nieuwenhuijzen, GA	1
van der Sangen, MJ	1
Hutschemaekers, S	1
Roukema, JA	1
Tjan-Heijnen, VC	1
Voogd, AC	1
Kashiwagi, S	1
Asano, Y	1
Morisaki, T	1
Nakamura, M	1
Kawajiri, H	1
Takashima, T	1
Onoda, N	1
Ishikawa, T	1
Hirakawa, K	1
Sakurai, T	3
Oura, S	2
Kinoshita, T	2
Yokochi, H	2
Enomoto, K	1
Nishimura, M	1
Okamura, Y	3
Suzuma, T	1
Yoshimura, G	1
Umemura, T	1
Shimizu, Y	1
Yang, QF	1
O'Neill, C	1
Howell, T	1
Forbes, J	1
Sonntag, M	1
Reifenberger, J	1
Megahed, M	1
Schulte, KW	1
Hirai, I	1
Tanino, H	1
Yoshimas, T	1
Kokawa, Y	1
Nishida, M	1
Sasaki, R	1
Bessho, T	1
Nishimura, O	1
Tse, EY	1
Loo, WT	1
Cheung, MN	1
Chow, LW	1
Cheng, CW	1
Chettle, C	1
Baker, MA	1
Yuasa, H	1
Katsumine, Y	1
Uehara, S	1
Noda, N	1
Osawa, I	1
Ryan, PD	1
Kopans, DB	1
Sgroi, DC	1
Rai, Y	1
Ando, M	1
Sagara, Y	2
Takahama, T	1
Matsuyama, Y	1
Ooi, Y	1
Erkanli, S	1
Kayaselcuk, F	1
Kuscu, E	1
Bolat, F	1
Sakalli, H	1
Haberal, A	1
Haberstich, R	1
Tuech, JJ	1
Wilt, M	1
Rodier, JF	1
Maciá Escalante, S	1
Pons Sanz, V	1
Rodríguez Lescure, A	1
Ballester Navarro, I	1
Carrato Mena, A	1
Giordano, SH	1
Hortobagyi, GN	1
Ohsako, T	1
Inoue, K	1
Nagamoto, N	1
Tanaka, E	1
Yoshida, Y	1
Sahin, FI	1
Yilmaz, Z	1
Karakuş, S	1
Boğa, S	1
Akçali, Z	1
DemIrhan, B	1
Li, HP	1
Ji, JF	1
Hou, KY	1
Jia, TZ	1
Zhao, HM	1
Xiao, Y	1
Wang, MP	1
Wang, YF	1
Perez-Fidalgo, JA	1
Chirivella, I	1
Laforga, J	1
Colio, JM	1
Blanes, MD	1
Baydal, R	1
Roselló, S	1
De-la-Morena, E	1
Lluch, A	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Randomized Phase III Trial Of Exemestane Versus Anastrozole In Postmenopausal Women With Receptor Positive Primary Breast Cancer[NCT00066573]	Phase 3	7,576 participants (Actual)	Interventional	2003-06-06	Completed
International Breast Cancer Intervention Study[NCT00078832]	Phase 3	3,864 participants (Actual)	Interventional	2003-09-30	Completed
Effects of Progressive Relaxation Training on Artralgia, Quality of Life and Emotional Status in Breast Cancer Patients Receiving Aromatatase Inhibitor Therapy[NCT04163692]		44 participants (Actual)	Interventional	2019-10-25	Completed
International Breast Cancer Intervention Study II (IBIS-II) (DCIS)[NCT00072462]	Phase 3	2,980 participants (Actual)	Interventional	2003-09-30	Completed
Ten Years Results of a Score System to Address Adjuvant Therapies After Breast Conserving Surgery for Ductal Carcinoma in Situ of the Breast.[NCT03002766]	Phase 2	224 participants (Actual)	Interventional	2000-03-31	Completed
A Clinical Trial Comparing Anastrozole With Tamoxifen in Postmenopausal Patients With Ductal Carcinoma in Situ (DCIS) Undergoing Lumpectomy With Radiation Therapy[NCT00053898]	Phase 3	3,104 participants (Actual)	Interventional	2003-01-31	Completed
A Randomized Multicenter Phase II Study Identifying Hormone Sensitivity Profiles and Evaluating the Efficacy of Anastrozole and Fulvestrant in the Neo-adjuvant Treatment of Operable Breast Cancer in Postmenopausal Women.[NCT00629616]	Phase 2	116 participants (Actual)	Interventional	2007-10-31	Completed
A Phase III Study to Evaluate Letrozole as Adjuvant Endocrine Therapy for Postmenopausal Women With Receptor (ER and/or PgR) Positive Tumors[NCT00004205]	Phase 3	8,028 participants (Actual)	Interventional	1998-03-31	Completed
Surrogate Markers of Response: A Phase II Study of Changes in Breast Density Among Postmenopausal Women Receiving Adjuvant Anastrozole Therapy[NCT00244959]	Phase 2	54 participants (Actual)	Interventional	2004-01-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Clinical fracture at any time, including hip, spine, wrist fractures and other bone fractures. (NCT00066573)
Timeframe: 8 years

Distant Disease-free Survival: Number of Participants Without Documented Distant Recurrence

Intervention	Participants (Count of Participants)
Exemestane	358
Anastrozole	354

Time to distant disease-free survival (DDFS) is defined as the time from randomization to the time of documented distant recurrence. Distant recurrence is the cancer coming back in a part of the body away from the breast, such as the bones or liver. (NCT00066573)
Timeframe: 5 years

Event-free Survival

Intervention	Participants (Count of Participants)
Exemestane	157
Anastrozole	164

Event free survival, the primary endpoint of this study, is defined as the time from randomization to the time of documented locoregional or distant recurrence, new primary breast cancer, or death from any cause. (NCT00066573)
Timeframe: 5 years

Overall Survival: Percentage of Participants Alive at 5 Years

Intervention	percentage of participants (Number)
Exemestane	88
Anastrozole	89

Overall survival is defined as the time from randomization to the time of death from any cause. (NCT00066573)
Timeframe: 5 years

Percentage of Patients Alive (Overall Survival)

Percentage of Patients Alive and Disease-free

Intervention	Percentage of Participants (Number)
Exemestane	92
Anastrozole	92

Intervention	percentage of participants event-free (Number)
Group 1: Tamoxifen + Anastrozole Placebo	92.1
Group 2: Anastrozole + Tamoxifen Placebo	92.5

Percentage of patients free from a disease-free survival event where events include any recurrence, second primary cancer, and death from any cause. Lobular carcinoma in situ (LCIS), basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the colon, melanoma in situ, and cervical carcinoma in situ will not be included as recurrences or second primary cancer. (NCT00053898)
Timeframe: 10 years

Percentage of Patients Free From Breast Cancer

Intervention	percentage of participants event-free (Number)
Group 1: Tamoxifen + Anastrozole Placebo	77.9
Group 2: Anastrozole + Tamoxifen Placebo	82.7

Percentage of patients free from breast cancer event at 10 years where events include local, regional, or distant recurrence or contralateral breast cancer, invasive or DCIS. (NCT00053898)
Timeframe: 10 years

Percentage of Patients Free From Contralateral Breast Cancer

Intervention	percentage of participants event-free (Number)
Group 1: Tamoxifen + Anastrozole Placebo	89.1
Group 2: Anastrozole + Tamoxifen Placebo	93.1

Percentage of patients free from a breast cancer recurrence in the contralateral breast (invasive and DCIS), occurring as a first cancer event. (NCT00053898)
Timeframe: 10 years

Percentage of Patients Free From Invasive Breast Cancer

Intervention	percentage of participants event-free (Number)
Group 1: Tamoxifen + Anastrozole Placebo	94.7
Group 2: Anastrozole + Tamoxifen Placebo	97.0

Percentage of patients free from an invasive breast cancer event where events include invasive local, regional, or distant recurrence, or contralateral breast cancer, occurring as a first cancer event. Note that this endpoint includes only invasive breast cancers and the primary endpoint includes both invasive and DCIS breast cancers. (NCT00053898)
Timeframe: 10 years

Percentage of Patients Free From Ipsilateral Recurrence

Intervention	percentage of participants event-free (Number)
Group 1: Tamoxifen + Anastrozole Placebo	93.3
Group 2: Anastrozole + Tamoxifen Placebo	96.4

Percentage of patients free from a breast cancer recurrence in the ipsilateral breast (invasive and DCIS), occurring as a first cancer event. (NCT00053898)
Timeframe: 10 years

Percentage of Patients Free From Non-breast Secondary Cancer

Intervention	percentage of participants event-free (Number)
Group 1: Tamoxifen + Anastrozole Placebo	94.6
Group 2: Anastrozole + Tamoxifen Placebo	96.4

Percentage of patients free from any non-breast second primary cancer other than squamous or basal cell carcinoma of the skin, carcinoma in situ of the colon, melanoma in situ, or carcinoma in situ of the cervix, occurring as a first cancer event. (NCT00053898)
Timeframe: 10 years

Percentage of Patients Free From Osteoporotic Fractures

Intervention	percentage of participants event-free (Number)
Group 1: Tamoxifen + Anastrozole Placebo	91.5
Group 2: Anastrozole + Tamoxifen Placebo	91.9

Percentage of patients free from fractures of the hip, spine, and wrist. (NCT00053898)
Timeframe: 10 years

Quality of Life-Short Form 12 (SF-12) Physical Health Component Score

Intervention	percentage of participants event-free (Number)
Group 1: Tamoxifen + Anastrozole Placebo	96.0
Group 2: Anastrozole + Tamoxifen Placebo	95.3

The primary outcome of the QOL substudy was the Medical Outcomes Study-Short Form 12 (SF-12) physical health component scale score. The SF-12 physical score was calculated to have a range of 0-100 and was normalized to have a mean of 50 and a standard deviation of 10 in the general population. Higher scores indicate better health. (NCT00053898)
Timeframe: 5 years

Quality-adjusted Survival Time

Intervention	units on a scale (Mean)
Group 1: Tamoxifen + Anastrozole Placebo	46.20
Group 2: Anastrozole + Tamoxifen Placebo	45.38

The mean quality-adjusted survival time (in months) in each treatment group, estimated by the Quality-Adjusted Time without Symptoms and Toxicity (Q-TWIST) method. (NCT00053898)
Timeframe: 10 years

Article	Year
Isolated Retinal Metastasis From Breast Cancer. Retina (Philadelphia, Pa.), 2017, Volume: 37, Issue:11 Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined	2017
Posterior reversible encephalopathy syndrome: more than meets the eye. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jul-10, Volume: 31, Issue:20 Topics: Anastrozole; Biopsy, Needle; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Co	2013
Breast cancer chemoprevention: little progress in practice? Lancet (London, England), 2014, Mar-22, Volume: 383, Issue:9922 Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Duc	2014
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer. Annals of surgical oncology, 2014, Volume: 21, Issue:5 Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo	2014
Case records of the Massachusetts General Hospital. Case 1-2015. A 66-year-old woman with metastatic breast cancer after endocrine therapy. The New England journal of medicine, 2015, Jan-08, Volume: 372, Issue:2 Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Duc	2015
Management of Premenopausal Women with Neoadjuvant Endocrine Therapy: A Single-Institution Experience. Annals of surgical oncology, 2015, Volume: 22, Issue:12 Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols;	2015
Risk factors for joint symptoms in postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes. International journal of clinical oncology, 2016, Volume: 21, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Duct	2016
[A Case of Locally Advanced Breast Cancer Treated with Modified Radical Mastectomy with Immediate Reconstruction Using a Tissue Expander after Endocrine Therapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:12 Topics: Anastrozole; Antineoplastic Agents, Hormonal; Biopsy, Large-Core Needle; Breast Implants; Breast Neo	2015
Exemestane-induced radiation recall dermatitis and morbilliform rash. The Journal of dermatology, 2016, Volume: 43, Issue:5 Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Arthralgia; Carcinom	2016
Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer. Nature communications, 2016, Feb-09, Volume: 7 Topics: AC133 Antigen; Anastrozole; Androstadienes; Animals; Antigens, CD; Antineoplastic Agents, Hormonal;	2016
Long-Term Disease-Free Survival in a Young Patient With Hormone Receptor-Positive Breast Cancer and Oligometastatic Disease in the Brain. Clinical breast cancer, 2016, Volume: 16, Issue:3 Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Carc	2016
Primary uterine rhabdomyosarcoma in a patient with a history of breast cancer and gastrointestinal stromal tumor. The journal of obstetrics and gynaecology research, 2008, Volume: 34, Issue:4 Pt 2 Topics: Aged; Anastrozole; Breast; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Gastrointestinal Str	2008
A remarkable case of cutaneous metastatic breast carcinoma. Dermatology online journal, 2009, Jul-15, Volume: 15, Issue:7 Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast	2009
[A successful case of advanced breast cancer of the elderly treated with the only breast-hormone therapy as PST]. Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:12 Topics: Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aortic Aneurysm, Thoracic; Aortic D	2009
A rare case of breast cancer metastasis. Breast disease, 2010, Volume: 31, Issue:1 Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Brea	2010
[Clinical significance and pathological evaluation of neoadjuvant chemotherapy in breast cancer]. Zhonghua bing li xue za zhi = Chinese journal of pathology, 2010, Volume: 39, Issue:4 Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antin	2010
Cost effectiveness of letrozole versus anastrozole in postmenopausal women with HR+ early-stage breast cancer. Current medical research and opinion, 2010, Volume: 26, Issue:10 Topics: Aged; Anastrozole; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Cost-Benefit	2010
[Advanced breast cancer in a patient achieving long-term SD after letrozole administration for liver metastasis developing during anastrozole therapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:13 Topics: Aged; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcino	2010
[A case of stage IV breast cancer with bone metastases that responded well for long-term to hormonal therapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:12 Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, B	2010
Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole. Cancer prevention research (Philadelphia, Pa.), 2011, Volume: 4, Issue:12 Topics: Aged; Anastrozole; Aromatase Inhibitors; Breast; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcin	2011
Hormone treatment without surgery for patients aged 75 years or older with operable breast cancer. Annals of surgical oncology, 2012, Volume: 19, Issue:4 Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neopla	2012
[A successful case of a super-elderly breast cancer patient treated with hormone therapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:12 Topics: Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Biopsy, Large-Core Needle; Breast N	2012
[Advanced breast cancer with lung and pleural metastases responsive to anastrozole--a case report]. Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:9 Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Duc	2002
Anastrozole-induced remission of diaphragmatic paralysis from metastatic breast cancer treated with multiple prior therapies. Breast cancer (Tokyo, Japan), 2003, Volume: 10, Issue:2 Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined	2003
Anastrozole for ductal carcinoma in situ. Lancet (London, England), 2003, Sep-06, Volume: 362, Issue:9386 Topics: Anastrozole; Antineoplastic Agents, Hormonal; Attitude to Health; Breast Neoplasms; Carcinoma in Sit	2003
[Ulcus terebrans. Therapy options and their limits]. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2004, Volume: 55, Issue:10 Topics: Aged; Anastrozole; Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Ductal, Breast; Combined Moda	2004
[Anastrozole-resistant breast cancer responsive to exemestane--a case report]. Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:12 Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast	2004
Arimidex inhibition on proliferation of human breast solid tumors measured by ATP bioluminescence. Life sciences, 2004, Dec-31, Volume: 76, Issue:7 Topics: Adenosine Triphosphatases; Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormo	2004
Remission of macroglobulinemia during anastrozole treatment for breast cancer. The New England journal of medicine, 2005, Apr-21, Volume: 352, Issue:16 Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinom	2005
[Three cases of advanced breast cancer successfully treated with a weekly dose of paclitaxel]. Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:4 Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone N	2005
Case records of the Massachusetts General Hospital. Case 24-2005. A 58-year-old woman with early-stage estrogen-receptor-positive breast cancer. The New England journal of medicine, 2005, Aug-11, Volume: 353, Issue:6 Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemother	2005
[Neoadjuvant endocrine therapy with anastrozole significantly downstaged an elderly breast cancer woman with locally-advanced breast cancer which became operable]. Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:9 Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Neoplasms; Carcinoma, Duc	2005
Lobular carcinoma of the breast metastatic to the uterus in a patient under adjuvant anastrozole therapy. Breast (Edinburgh, Scotland), 2006, Volume: 15, Issue:4 Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Duc	2006
Anal localization as first manifestation of metastatic ductal breast carcinoma. Techniques in coloproctology, 2005, Volume: 9, Issue:3 Topics: Aged; Anastrozole; Anus Neoplasms; Biopsy, Needle; Breast Neoplasms; Carcinoma, Ductal, Breast; Chem	2005
Primary hormone treatment in postmenopausal women with breast cancer. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2006, Volume: 8, Issue:5 Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast	2006
Leuprolide acetate plus aromatase inhibition for male breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jul-20, Volume: 24, Issue:21 Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy P	2006
[Locally advanced breast cancer with a good response to sequential endocrine monotherapy--a case report]. Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:1 Topics: Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; C	2007
t(8;16) AML developed subsequent to breast cancer therapy. Hematology (Amsterdam, Netherlands), 2006, Volume: 11, Issue:3 Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone M	2006
[Clinical study of aromatase inhibitors in advanced breast cancer]. Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2007, Apr-18, Volume: 39, Issue:2 Topics: Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bre	2007
Parotid gland metastasis of a breast cancer. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2007, Volume: 9, Issue:4 Topics: Anastrozole; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Al	2007

anastrozole and Carcinoma, Ductal, Breast